Imprimis Pharmaceuticals Inc (IMMY.OQ)
19 Mar 2018
* IMPRIMIS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER 2017 RESULTS
* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:
BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility
* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:
Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.
* Imprimis Pharmaceuticals announces third quarter 2017 results
Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.
BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1
* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1 Further company coverage:
* Imprimis Pharmaceuticals-making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis Source text for Eikon: Further company coverage: